Company Overview and News

 
Will Castrol tie-up with M&M add fuel?

2018-10-11 thehindubusinessline
Shares of Castrol India will remain in focus, as the company on Thursday signed a new strategic partnership with Mahindra & Mahindra. Under the pact, M&M will endorse a range of Castrol products which include aftermarket engine oils and transmission fluids for Mahindra tractors. Based on formulation exclusively developed by M&M for use in its tractors, Castrol will supply these products through its distribution network.
CASTROLIND CSLQY 500870

 
Castrol India Limited - Updates

2018-10-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CASTROLIND CSLQY 500870

 
Value Hunting Overseas Continued

2018-10-08 seekingalpha
All metrics are still indicating a US stock market bubble (at least forming up), while overseas markets demonstrate relative values.
RTLLF CASTROLIND BKNG FUPEF KKKUF KKMMY FUPEY RATIY FUPBY CSLQY 500870

 
Oil and gas stocks slide up to 12%

2018-10-04 financialexpress
The Oil and gas stocks were among the worst hit on Thursday after the Centre announced a Rs 2.50 per litre cut in petrol and diesel prices. The Centre cut the excise duty by Rs 1.50 a litre, and asked the oil companies to absorb another Rs 1. Shares of state-run OMCs Hindustan Petroleum (HPCL), Bharat Petroleum (BPCL) and Indian Oil (IOC) plummeted by up to 12%, while the BSE Oil and Gas Index closed the day 6.
IOC 500325 BPCL 500547 RELIANCE PQRTY 530965 PETRONET 532514 532522 CSLQY IGL 533106 CASTROLIND OIL BRQPY RIGD GAILY GAILF RLNIY 500870

 
Castrol India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CASTROLIND CSLQY 500870

 
D-Street Buzz: Nifty pharma outperforms with Sun Pharma up 2%; RIL advances, Advanced Enzyme jumps 9%

2018-09-05 moneycontrol
The Indian benchmark indices are trading on a flat to positive note this Wednesday morning with the Nifty50 trading at 11,521, up 1 point while the Sensex is trading higher by 38 points at 38,196.
ESL SUZLON MUTHOOTFIN 500325 AUROPHARMA RELIANCE 533398 TATACOMM 532733 CADILAHC CSLQY 532321 532221 SONATSOFTW RIGD AJANTPHARM 520086 GAILF BEL SUEL SUNTV RLNIY 500870 BHQRY 524804 533264 532667 CDLYY CASTROLIND 532331 ARBQY GAILY SICAL SNQVY 500049 500483

 
Castrol India Limited - Updates

2018-08-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CASTROLIND CSLQY 500870

 
Castrol Q2 net profit up 19% at Rs 164 cr

2018-07-31 moneycontrol
Castrol India today posted 19 percent increase in its net profit at Rs 164.2 crore for the second quarter ended June 30, driven by higher volume as well as improved margin.
CASTROLIND CSLQY 500870

 
Castrol India Limited - Outcome of Board Meeting

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CASTROLIND CSLQY 500870

 
Castrol India Limited - Dividend

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CASTROLIND CSLQY 500870

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...